findmyKOL

Jing Chen, MD

Enriched profile

Professor, Department of Internal Medicine (Division of Nephrology) and Department of Public Health (O'Donnell School of Public Health); holds the Makoto Kuro-o Professorship in Bone and Kidney Research · The University of Texas Southwestern Medical Center

ORCIDNPI
Region🇺🇸 Dallas, TX · South Central · United StatesSpecialtyNephrologyFocusChronic Kidney Disease
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceNone verifiedPayments2021–2024NIH fundingNone on fileWhy? →

Jing Chen is Professor, Department of Internal Medicine (Division of Nephrology) and Department of Public Health (O'Donnell School of Public Health); holds the Makoto Kuro-o Professorship in Bone and Kidney Research at The University of Texas Southwestern Medical Center. OpenAlex indexes 380 publications with 17,224 citations (h-index 55); ClinicalTrials.gov lists 26 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Nephrology profiles in the findmyKOL directory.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Jing Chen, MD, is Professor, Department of Internal Medicine (Division of Nephrology) and Department of Public Health (O'Donnell School of Public Health) at The University of Texas Southwestern Medical Center. The public record shows 380 publications with 17,224 citations (h-index 55), centered on Chronic Kidney Disease. It also documents an investigator role on 26 registered clinical trials, industry payments reported by 3 companies.

  • Most recent indexed publication: 2026 · Clinical journal of the American Society of Nephrology
  • Top research focus: Chronic Kidney Disease
  • 26 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 3 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Chronic Kidney Disease9 trialsESRD / Dialysis3 trialsHyperparathyroidism2 trialsST Elevation Myocardial Infarction2 trialsRenal Insufficiency2 trialsSarcoma2 trialsComa2 trialsGraft vs Host Disease2 trialsInfarction2 trialsHyperparathyroidism, Secondary1 trialCognitive Dysfunction1 trialMalnutrition1 trialFrailty1 trialChronic Kidney Disease-Mineral and Bone Disorder1 trialHypertension1 trialDyslipidemia / Lipid Disorders1 trialDyslipidemias1 trialThalassemia1 trialSarcopenia1 trialCoronary Artery Disease / ACS1 trialMyocardial Infarction1 trialInfarction, Middle Cerebral Artery1 trialDepression (MDD)1 trialProteinuria1 trialLymphoma1 trialPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trialRecurrence1 trialStroke1 trialCerebrovascular Disorders1 trialNeoplasms, Connective and Soft Tissue1 trial

Research focus

OpenAlex concept fingerprint
Chronic Kidney Disease

Drugs & molecules

across trials, industry payments and publications
Vafseogeneric · VadadustatClinical trialsIndustry payments2PublicationsFabrazymegeneric · Agalsidase betaClinical trialsIndustry payments1PublicationsVeltassageneric · PatiromerClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
Huashan HospitalClinical trials10Industry paymentsAkebia Therapeutics IncClinical trialsIndustry payments2Shanghai Children's Medical CenterClinical trials2Industry payments

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
380publications

Distinct works indexed by OpenAlex, matched via ORCID; 26 in PubMed.

17,224citations

Total citations across indexed works.

55h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
26clinical trials

Investigator role on registered studies.

View trials
3companies · 2021–2024

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 26 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

3 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    51.5%
    SGLT2 inhibitor51.5%
    Jardiance100%
    Part D<11 patients
  • Blood & clotting

    48.5%
    Erythropoiesis-stimulating Agent48.5%
    Procrit100%
    Part D<11 patients
Where care is delivered (Part B), 2022100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record
1 more award behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.